Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2008-04-01
2008-04-01
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S184100, C424S189100, C424S204100, C424S227100, C424S278100, C530S350000
Reexamination Certificate
active
10677074
ABSTRACT:
A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule.
REFERENCES:
patent: 4539205 (1985-09-01), Goodman et al.
patent: 4643992 (1987-02-01), Goodman et al.
patent: 4767842 (1988-08-01), Stevens
patent: 4818527 (1989-04-01), Thornton et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 4977092 (1990-12-01), Bitter
patent: 5011828 (1991-04-01), Goodman et al.
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5093318 (1992-03-01), Goodman et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5478726 (1995-12-01), Shinnick et al.
patent: 5656472 (1997-08-01), Ausich et al.
patent: 5709879 (1998-01-01), Barchfeld et al.
patent: 5990085 (1999-11-01), Ireland et al.
patent: 6020167 (2000-02-01), Thoma
patent: 6024961 (2000-02-01), Curtiss, III et al.
patent: 6086901 (2000-07-01), O'Hagan et al.
patent: 6113918 (2000-09-01), Johnson et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6303347 (2001-10-01), Johnson et al.
patent: 6355257 (2002-03-01), Johnson et al.
patent: 6942866 (2005-09-01), Birkett
patent: 6964769 (2005-11-01), Sebbel et al.
patent: 2003/0092643 (2003-05-01), Johnson et al.
patent: WO 92/11368 (1992-07-01), None
patent: 671 948 (1995-09-01), None
patent: 689 454 (1996-01-01), None
patent: WO 95/17210 (1995-06-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 96/33739 (1996-10-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/12565 (1999-03-01), None
patent: WO 99/52549 (1999-10-01), None
patent: WO 99/56776 (1999-11-01), None
patent: WO 01/16163 (2001-03-01), None
patent: WO 01/27281 (2001-04-01), None
patent: WO 01/98333 (2001-12-01), None
patent: WO 02/13765 (2002-02-01), None
patent: WO 02/14478 (2002-02-01), None
patent: WO 2005/055957 (2005-06-01), None
Akira et al., “Recognition of pathogen-associated molecular patterns by TLR family,” Immunology Letters, vol. 85 No. 2, pp. 85-95 (Jan. 2003).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Jung et al., “Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection,” Journal of Virology, vol. 69 No. 6, pp. 3358-3368 (Jun. 1995).
Lebray et al., “Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection,” Journal of Hepatology, vol. 39 Supp 1, pp. S151-159 (2003).
Riffkin et al., “A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 from Dichelobacter nodosus,” Gene, vol. 167 No. 1-2, pp. 279-283 (Dec. 1995).
Sarobe et al., “Enhanced In Vitro Potency and In Vivo Immunogenicity of a CTL Epitope from Hepatitis C Virus Core Protein following Amino Acid Replacement at Secondary HLA-A2.1 Binding Positions ,” Journal of Clinical Investigation, vol. 102 No. 6, pp. 1239-1248 (Sep. 1998).
Sieling and Modlin, “Toll-like receptors: mammalian ‘taste receptors’ for a smorgasbord of microbial invaders,” Current Opinion in Microbiology, vol. 5 No. 1, pp. 70-75 (Feb. 2002).
Sprengers et al., “Immunomodulatory therapy for chronic hepatitis B infection,” Fundament & Clinical Pharmacology, vol. 19 No. 1, pp. 17-26 (Feb. 2001).
Yuen et al., “Treatment of chronic hepatitis B,” The Lancet: Infectious Diseases, vol. 1 No. 4, pp. 232-241 (Nov. 2001).
BLAST search results- Seq ID No. 28, translated query verse protein database.
Zhou et al., “Cys residues of the hepatitis B virus capsid protein are not essential for the assembly of viral core particles but can influence their stability,” Journal of Virology, vol. 66 No. 9, pp. 5393-5398 (Sep. 1992).
Couillin et al. (1999) J. of Infect. Dis., 180: 15-26.
Bocher et al. (2001) E. J. of Immun., 31:2071-2079.
Lau et al. (2002) Gastroenterology, 122:614-624.
Sallberg et al., (1998) Human Gene Therapy 10:1719-1729.
Pumpens et al.Intervirology(1995) 38:63-74.
Metzger et al.J. Gen. Viol.(1998) 79:587-590.
Conway et al.Nature(1997) 386:91-94.
Bottcher et al.Nature(1997) 386:88-91.
Zheng et al. J.Biol. Chem.(1992) 267(13):9422-9429.
Birnbaum et al., (1990)J.Virol.64, 3319-3330.
Clarke et al. (1991) F. Brown et al. eds.,Vaccines 91, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 313-318.
Seifer et al., (1995) Intervirology, 38:47-62.
Zlotnick et al., (1997)Proc. Natl. Acad. Sci., USA, 94:9556-9561.
Gallina et al. (1989)J.Virol.,63:4645-4652.
Inada, et al. (1989)Virus Res.,14:27-48.
Maassen et al., (1994)Arch. Virol.,135:131-142.
Schodel et al., (1994)J.Exp.Med.,180:1037-1046.
Schodel et al. (1994)Infect. Immunol.,62:1669-1676.
Kratz et al., (1999)Proc. Natl. Acad. Sci., U.S.A.,96:1915-1920.
Ulrich et al.Adv. Virus Res.,50: 141-182 (1998) Academic Press.
Neirynck et al., (Oct. 1999)Nature Med.,5(10):1157-1163.
Schodel et al. (Jan. 15, 1993)J. Biol. Chem.,268(2):1332-1337.
Wasenauer et al. (Mar. 1993)J. Virol.,67(3):1315-1322.
Nassal et al. (Jul. 1993)J. Virol.,67(7):4307-4315.
Galibert et al. (1983)Nature, 281:646-650.
Ono et al. (1983)Nucleic Acids Res.,11(6): 1747-1757.
Valenzuela et al.,Animal Virus Genetics, Field et al. eds., Academic Press, New York (1980)pp. 57-70.
Pasek et al., “Hepatitis B virus genes and their expression inE. coli”, Nature(Dec. 1979) 282:575-579.
Galibert et al. (1982)J. Virol.,41:51-65.
Seeger et al. (1984)J. Virol.,51:367-375.
“IUPAC-IUB Commission on Biochemical Nomenclature A One-Letter Notation for Amino Acid Sequences1-3Tentative Rules”,J. Biol. Chem.(Jul. 1968) 243(13):3557-3559.
Karpenko et al.,Amino Acids(2000) 18:329-337.
Koschel et al. (Mar. 1999),J. Virol.,73(3):2153-2160.
Schodel et al., “Hybrid Hepatitis-B Virus Core/Pre-S Particles Expressed In Live AttenuatedSalmonellaefor Oral Immunization”,Vaccines(1991) 91, Cold Spring Harbor Laboratory, New York, pp. 319-325.
Schodel et al.,Behring Inst. Mitt.,1997(98): p. 114-119.
Schodel et al., “Recombinant HBV Core Particles Carrying Immunodominant B-Cell Epitopes of the HBV Pre-S2 Region”,Vaccines(1990) 90, Cold Spring Harbor Laboratory, New York, pp. 193-198.
Poszkowski et al. (1989)EMBO J.,3:2719.
Odell et al.Nature(1985), 313:810.
Chua et al.Science(1989), 244:174-181.
Nestle et al (2001)Nature Medicine7, 761-765.
Lebray et al, Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection,J. of Hepatology, 2003, 39:S151-159.
Nardin et al., Phase I Testing of a Malaria Vaccine Compound of Hepatits B Virus Core Particles ExpressingPlasmodium falciparumCircumsporozoite Epitopes,Infection and Immunity, vol. 72, No. 11, pp. 6519-6527 2004.
Oliveira et al, Safety and Enhanced Immunogenicity of a Hepatitis B Core ParticlePlasmodium falciparumMalaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial,Infection and Immunity, Jun. 2005, vol. 73, No. 6, pp. 3587-3597.
PCT/US04/05047 International Search Report, mailed Jul. 17, 2006.
Office Action from Patent and Trademark Office for corresponding U.S. Appl. No. 10/732,862, dated Mar. 17, 2004.
Office Action from Patent and Trademark Office for corresponding U.S. Appl. No. 10/732,862, dated Dec. 17, 2004.
Office Action from Patent and Trademark
Friede Martin
Page Mark
Schmidt Annette Elisabeth
Stober Detlef
Lorantis Limited
Lucas Zachariah
Welsh & Katz Ltd.
LandOfFree
Stabilized HBc chimer particles as immunogens for chronic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized HBc chimer particles as immunogens for chronic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized HBc chimer particles as immunogens for chronic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3926245